Home » Stocks » CBPO

China Biologic Products Holdings, Inc. (CBPO)

Stock Price: $118.64 USD -0.17 (-0.14%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 4.67B
Revenue (ttm) 514.40M
Net Income (ttm) 141.06M
Shares Out 38.69M
EPS (ttm) 3.57
PE Ratio 33.23
Forward PE 21.01
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $118.64
Previous Close $118.81
Change ($) -0.17
Change (%) -0.14%
Day's Open 118.65
Day's Range 118.27 - 118.80
Day's Volume 87,413
52-Week Range 99.15 - 118.99

More Stats

Market Cap 4.67B
Enterprise Value 3.57B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.69M
Float n/a
EPS (basic) 3.65
EPS (diluted) 3.57
FCF / Share 6.38
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.01%
FCF Yield 5.29%
Payout Ratio n/a
Shares Short 519,024
Short Ratio 6.59
Short % of Float n/a
Beta 0.45
PE Ratio 33.23
Forward PE 21.01
P/FCF Ratio 18.92
PS Ratio 9.08
PB Ratio 2.44
Revenue 514.40M
Operating Income 181.33M
Net Income 141.06M
Free Cash Flow 246.82M
Net Cash 1.10B
Net Cash / Share 28.03
Gross Margin 63.97%
Operating Margin 35.25%
Profit Margin 27.40%
FCF Margin 47.98%
ROA 5.62%
ROE 8.94%
ROIC 19.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$111.00*
(-6.44% downside)
Low
103
Current: $118.64
High
119
Target: 111.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue504467370341296243203185153140
Revenue Growth7.9%26.04%8.57%15.08%21.87%19.62%10.03%20.72%9.59%-
Gross Profit329320245217190163138126107103
Operating Income16414613614413311186.9374.4932.2268.57
Net Income13912867.9410589.0470.9254.6045.2218.1831.54
Shares Outstanding38.6635.3027.3626.8525.6024.4326.4126.1525.0323.59
Earnings Per Share3.533.532.383.743.272.711.961.620.371.30
EPS Growth0%48.32%-36.36%14.37%20.66%38.27%20.99%337.84%-71.54%-
Operating Cash Flow22910410212310993.5174.3071.1038.4738.79
Capital Expenditures-19.72-31.62-37.44-38.68-37.96-15.34-20.30-13.80-7.91-10.31
Free Cash Flow21072.3264.7484.5871.4378.1854.0157.2930.5628.47
Cash & Equivalents92795228818418318518113389.4164.94
Total Debt-----97.9039.827.9411.024.23
Net Cash / Debt92795228818418386.8314112578.3960.71
Assets1,9382,010809605551447404311249221
Liabilities16316514583.8284.5017299.8153.6369.8575.88
Book Value1,6961,72259846238221223819513699.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name China Biologic Products Holdings, Inc.
Employees 2,246
CEO David Gao

Stock Information

Ticker Symbol CBPO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBPO

Description

China Biologic Products Holdings engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.